Your browser doesn't support javascript.
Medical Significance of Uterine Corpus Endometrial Carcinoma Patients Infected With SARS-CoV-2 and Pharmacological Characteristics of Plumbagin.
Li, Yongming; Yu, Songzuo; Li, Yu; Liang, Xiao; Su, Min; Li, Rong.
  • Li Y; Department of Gynecology, Guigang Maternal and Child Health Care Hospital, Guigang, China.
  • Yu S; Department of Neurosurgery, Guigang City People's Hospital, The Eighth Affiliated Hospital of Guangxi Medical University, Guigang, China.
  • Li Y; Laboratory of Environmental Pollution and Integrative Omics, Guilin Medical University, Guilin, China.
  • Liang X; Laboratory of Environmental Pollution and Integrative Omics, Guilin Medical University, Guilin, China.
  • Su M; Laboratory of Environmental Pollution and Integrative Omics, Guilin Medical University, Guilin, China.
  • Li R; Guangxi Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin, China.
Front Endocrinol (Lausanne) ; 12: 714909, 2021.
Article in English | MEDLINE | ID: covidwho-1497067
ABSTRACT

Background:

Clinically, evidence shows that uterine corpus endometrial carcinoma (UCEC) patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may have a higher death-rate. However, current anti-UCEC/coronavirus disease 2019 (COVID-19) treatment is lacking. Plumbagin (PLB), a pharmacologically active alkaloid, is an emerging anti-cancer inhibitor. Accordingly, the current report was designed to identify and characterize the anti-UCEC function and mechanism of PLB in the treatment of patients infected with SARS-CoV-2 via integrated in silico analysis.

Methods:

The clinical analyses of UCEC and COVID-19 in patients were conducted using online-accessible tools. Meanwhile, in silico methods including network pharmacology and biological molecular docking aimed to screen and characterize the anti-UCEC/COVID-19 functions, bio targets, and mechanisms of the action of PLB.

Results:

The bioinformatics data uncovered the clinical characteristics of UCEC patients infected with SARS-CoV-2, including specific genes, health risk, survival rate, and prognostic index. Network pharmacology findings disclosed that PLB-exerted anti-UCEC/COVID-19 effects were achieved through anti-proliferation, inducing cytotoxicity and apoptosis, anti-inflammation, immunomodulation, and modulation of some of the key molecular pathways associated with anti-inflammatory and immunomodulating actions. Following molecular docking analysis, in silico investigation helped identify the anti-UCEC/COVID-19 pharmacological bio targets of PLB, including mitogen-activated protein kinase 3 (MAPK3), tumor necrosis factor (TNF), and urokinase-type plasminogen activator (PLAU).

Conclusions:

Based on the present bioinformatic and in silico findings, the clinical characterization of UCEC/COVID-19 patients was revealed. The candidate, core bio targets, and molecular pathways of PLB action in the potential treatment of UCEC/COVID-19 were identified accordingly.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Naphthoquinones / Endometrial Neoplasms / Carcinoma, Endometrioid / Host-Pathogen Interactions / COVID-19 Type of study: Diagnostic study / Prognostic study Topics: Long Covid Language: English Journal: Front Endocrinol (Lausanne) Year: 2021 Document Type: Article Affiliation country: Fendo.2021.714909

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Naphthoquinones / Endometrial Neoplasms / Carcinoma, Endometrioid / Host-Pathogen Interactions / COVID-19 Type of study: Diagnostic study / Prognostic study Topics: Long Covid Language: English Journal: Front Endocrinol (Lausanne) Year: 2021 Document Type: Article Affiliation country: Fendo.2021.714909